| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11333184 | IVR | 937 mg/kg/day | - | No significant effects observed | - |
| IVR | 611 mg/kg/day | - | No significant effects observed | - | |
| IVR | 1525 mg/kg/day | 1525 mg/kg/day | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.00005 M | 0.000005 - 0.00005 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:15458797 | IVR | 250 mg/kg | 250 mg/kg | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| IVR | 250 mg/kg | 250 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 250 mg/kg | 250 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Increased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | 1000 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:28990245 | IVTH | 0.00001 M | 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.0000001 M | 0.0000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:30057971 | IVR | 0.212 mg/kg/day | 0.212 mg/kg/day | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations |
| IVR | 0.212 mg/kg/day | 0.212 mg/kg/day | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.212 mg/kg/day | 0.212 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Induce tumor progression | Endocrine-mediated cancer | |
| PMID:31408669 | IVR | 0.212 mg/kg/day | 0.212 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.212 mg/kg/day | 0.212 mg/kg/day | Affects anogenital distance in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Affects expression of estrogen receptor-alpha (ER-alpha) in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.